SII collaborates with Univercells on personalized cancer care

In a landmark collaboration announced today, Serum Institute of India (SII), the world’s largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator, targeting a dramatic increase in accessibility to personalized cancer care.

This partnership aims to bring cutting edge treatment options within reach of millions globally. At present, personalized care options such as novel cancer vaccines and specialized immunotherapies are accessible to a few patients only.

These new therapies are developed using genetic material extracted from the patient’s tumors, a process which is both time-consuming, and expensive.